Introduction
============

Skeletal muscle depletion, an indicator of sarcopenia, is associated with poor physical function and nutritional statuses.[@b1-cmar-10-2499] The skeletal muscle index (SMI), which can be easily evaluated using computed tomography (CT), has increasingly attracted research attention. For example, in a surgical context, a low SMI was associated with an increased incidence of surgical site infection and prolongation of the hospital stay.[@b2-cmar-10-2499],[@b3-cmar-10-2499] Moreover, a low SMI has been shown to impair survival and increase chemotherapy-related toxicity.[@b4-cmar-10-2499]

A recent study described cross-talk between systemic inflammation and sarcopenia;[@b5-cmar-10-2499] specifically, systemic inflammation may contribute to muscle breakdown, which in turn leads to an enhanced inflammatory response. Cancer cells can cooperate with other cells in the microenvironment and trigger inflammation, a process with various cytokines released.[@b6-cmar-10-2499] The cytokines may contribute to the loss of muscle mass. Additionally, Feliciano et al[@b5-cmar-10-2499] identified a positive association between an increased neutrophil-to-lymphocyte ratio (NLR) and the incidence of sarcopenia in patients with colorectal cancer (CRC). However, the potential associations of sarcopenia with other systemic inflammatory indexes, such as platelets, monocytes, and C-reactive protein (CRP) levels, remain to be studied.[@b7-cmar-10-2499],[@b8-cmar-10-2499] To our knowledge, no prior study has evaluated the association between the SMI and local tumor environmental factors, such as infiltrating neutrophils and lymphocytes.

Against this background, we aimed to investigate the relationships of the SMI with both systemic and local inflammatory factors in patients with CRC. We additionally studied the correlations of the SMI and with the circulating levels of cytokines in a cohort of patients who previously underwent cytokine analysis.[@b9-cmar-10-2499]

Patients and methods
====================

Patient selection
-----------------

This study was approved by the ethics review board of Sun Yat-sen University Cancer Center. All included patients met the following criteria: 1) primary tumor resection and pathological diagnosis of colon cancer at Sun Yat-sen University Cancer Center between 2009 and 2014; 2) available pretreatment routine blood analysis records; 3) available pre-surgical CT images; and 4) available follow-up information. Patients with infections, hematological disease, hyperpyrexia, intestinal perforation, or intestinal obstruction at diagnosis were excluded. All patients provided written informed consent to participate in the study.

Clinical and pathological data
------------------------------

A dataset was constructed prospectively at Sun Yat-sen University Cancer Center. The following data were retrospectively collected from medical records: age, sex, height, weight, primary tumor location, TNM staging, differentiation, mucinous histology, primary tumor size, neural invasion, venous invasion, mismatch repair status, and carcinoembryonic antigen (CEA) status. The following systemic inflammation markers were also analyzed: leukocyte, neutrophil, lymphocyte, monocyte, platelet counts, and albumin and CRP levels. Routine blood analyses were conducted using a Sysmex XE-5000™ Automated Hematology System (Sysmex, Shanghai, People's Republic of China). CRP levels were tested using a Hitachi Automatic Analyzer 7600-020 (Hitachi, Tokyo, Japan). CEA levels were evaluated using a Roche 2010 Chemistry Analyzer (F. Hoffmann-La Roche Ltd, Basel, Switzerland). The NLR, calculated as the ratio of neutrophil to lymphocyte counts, was used to stratify patients into 2 groups (NLR \>3 and ≤3).

Two pathologists blinded to the clinical data assessed the carcinoma percentage, neutrophil infiltration (both central region and invasive margin), lymphocyte infiltration (central region and invasive margin), and Crohn's-like reactions, as previously reported.[@b10-cmar-10-2499],[@b11-cmar-10-2499] Inflammatory cell reactions (neutrophils and lymphocytes) were estimated by screening the central tumor areas and invasive margins in hematoxylin and eosin-stained histological sections. All sections containing the most invasive part of the primary tumor were selected to avoid bias, and 4--6 sections were routinely evaluated per tumor. We used a 4-degree scale to assess the infiltration of neutrophils and lymphocytes. A score of 0 indicated an absence of reaction, 1 was weak, 2 indicated moderate, and 3 was severe increase of each cell type. Absent and weak (0--1) were combined as low grade, while moderate to severe increase (2--3) were high grade. If the 2 pathologists reached different conclusions, an agreement was reached through careful discussion.

The following cytokines were analyzed in a cohort of patients with metastatic CRC: IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, IL-15, IL-17, IL-12 P40, IL-12 P70, EGF, eotaxin, G-CSF, GM-CSF, IFNα-2, IFNγ, interferon γ-induced protein 10 (IP-10), MCP-1, MCP-3, MIP-1α, MIP-1β, TNFα, TNFβ, VEGF, FGF-2, TGF-α, FIT-3L, fractalkine, GRO, MDC, sCD40L, and sIL-2Rα.

Measurement of SMI
------------------

The baseline (ie, 1 month before surgery) enhanced CT images (slice thickness: 5 mm) were used to evaluate the SMI. One radiologist identified a single axial image at the third lumbar vertebral level on which both transverse processes were initially fully visualized.[@b12-cmar-10-2499] The axial CT image was then analyzed using the semiautomated GE Reformat postprocessing tool supplied with the GE picture archiving and communication systems workstation (Centricity® Radiology RA1000; GE Medical Healthcare, Little Chal-font, UK) to determine the cross-sectional skeletal muscle at a Hounsfield unit threshold of −29 to 150, as previously described.[@b13-cmar-10-2499] The skeletal muscle area was then quantified automatically and recorded. The following skeletal muscles were measured: psoas, erector spinae, quadratus lumborum, transversus abdominis, external and internal obliques, and rectus abdominis. The SMI was calculated by dividing the skeletal muscle area by the height squared (cm^2^/m^2^). Most previous studies of sarcopenia in patients with CRC have been conducted in Western countries, and accordingly no consensus has been reached regarding the optimal SMI cut-off point for defining sarcopenia in Asian patients with CRC. In our study, therefore, we classified patients into low and high SMI groups according to the median SMI values for men and women, respectively.

Patient treatment and follow-up
-------------------------------

Patients with colon cancer underwent primary tumor resection at our hospital. All patients were chemotherapy-naïve before surgery, and no adjuvant chemotherapy was provided to patients with stage I colon cancer. The administration of adjuvant chemotherapy to patients with stage II colon cancer was determined based on the patient's risk factors and physician's decision. Patients with stage III colon cancer were administered \~6-month course of oxaliplatin-based adjuvant chemotherapy. All patients were followed up through outpatient visits and telephone interviews. The last date of follow-up was August 31, 2017.

Statistical analyses
--------------------

All statistical analyses were performed using SPSS version 22 (IBM Corporation, Armonk, NY, USA). Frequencies and descriptive statistics were used to compare patient characteristics, and relationships between 2 continuous variables were tested using nonparametric tests or Pearson correlation coefficients as appropriate. Disease-free survival (DFS) was defined as the time from diagnosis to the time of the first event (locoregional recurrence, metastasis, or death). Survival curves were calculated using the Kaplan--Meier method and compared using the log-rank test. A multivariate analysis based on a Cox proportional hazards model was used to test independent significance via the backward elimination of insignificant explanatory variables. A *P*-value of \<0.05 was considered to indicate statistical significance.

Results
=======

Patient characteristics
-----------------------

The study cohort included 343 men and 218 women with a median age of 59 years (range: 19--87 years). Of them, 210 (37.4%) patients had right-sided colon cancer and 346 (61.7%) had left-sided colon cancer. The median SMIs for men and women were 44.1 and 34.2 cm^2^/m^2^, respectively.

Notably, 383 (68.3%) patients met the definition of sarcopenia according to the cut-off point used in the study by Feliciano et al.[@b5-cmar-10-2499] The distributions of the patients' clinicopathological features and their correlations with the SMI are shown in [Table 1](#t1-cmar-10-2499){ref-type="table"}. Particularly, a low SMI was associated with increasing age (*p*\<0.001), a larger primary tumor (*p*=0.018), and a lower body mass index (*p*\<0.001).

SMI and inflammatory factors
----------------------------

SMI was not found to correlate with local inflammatory reactions, as shown in [Table 2](#t2-cmar-10-2499){ref-type="table"}. Then, we studied the relation between SMI and systemic inflammatory response. Among 280 patients with a low SMI, 96 (34.3%) had an NLR \>3, whereas only 71 (25.3%) of 281 patients with a high SMI had an NLR \>3 among (*p*=0.021). Similarly, a low SMI was found to correlate significantly with a decreased albumin level (*p*=0.006), but not with the CRP level (*p*=0.129).

To further evaluate the relationship between the SMI and systemic inflammatory response, correlations of the absolute SMI values with the leukocyte, neutrophil, lymphocyte, monocyte, and platelet counts and CRP levels were investigated ([Figure 1](#f1-cmar-10-2499){ref-type="fig"}). Notably, we found that the SMI correlated positively with leukocyte (*p*=0.019), neutrophil (*p*=0.022), lymphocyte (*p*=0.001), and monocyte counts (*p*=0.003) and negatively with the platelet count (*p*=0.017). No significant correlation was observed between the SMI and CRP level (*p*=0.402).

Survival according to SMI and tumor stage
-----------------------------------------

The survival data for all 561 patients included in this study are shown in [Figure S1](#SD1-cmar-10-2499){ref-type="supplementary-material"}. The 3-year DFS rates were 57.0% in the low SMI population and 56.4% in the high SMI population, indicating a lack of a significant association of the SMI with DFS (HR =1.025; *p*=0.950) in patients with stage I + II disease. However, the SMI was found to have prognostic value in patients with stage III disease, with 3-year DFS rates of 35.1% in the low SMI population and 46.0% in the high SMI population (HR =2.036; *p*=0.034; [Figure 2](#f2-cmar-10-2499){ref-type="fig"}). Furthermore, a multivariate analysis revealed that the prognostic value of the SMI was independent of age, sex, T stage, N stage, the CEA level, and NLR ([Table 3](#t3-cmar-10-2499){ref-type="table"}).

Associations of SMI with circulating levels of cytokines
--------------------------------------------------------

We previously tested the circulating levels of cytokines in another cohort of 176 patients with CRC,[@b9-cmar-10-2499] including 125 patients with colon cancer and available CT scan data within 1 month after diagnosis. The clinical characteristics of these patients are shown in [Table S1](#SD2-cmar-10-2499){ref-type="supplementary-material"}. A decreased SMI was found to associate with an increased IP-10 level (*r* = −0.276, *p*=0.002; [Figure 3](#f3-cmar-10-2499){ref-type="fig"}). No associations were observed between the SMI and other cytokines.

Discussion
==========

In this study of patients with colon cancer, we found that a low SMI was associated with an increased NLR and decreased albumin level. Additionally, we observed a negative correlation between the SMI and circulating IP-10 level and confirmed a high SMI as a predictor of a better prognosis in patients with stage III colon cancer. By contrast, we did not observe an association between the SMI and tumor local inflammatory environment in our patient cohort.

The exact mechanism underlying the correlation between the SMI and inflammation in patients with colon cancer remains elusive.[@b5-cmar-10-2499] In this study, we found that a low SMI correlated with an increased IP-10 level, which was previously found to indicate a poor prognosis and higher levels of systemic inflammation markers in patients with colon cancer.[@b14-cmar-10-2499],[@b15-cmar-10-2499] The previous findings that IP-10 expression can be downregulated by running and vitamin D[@b16-cmar-10-2499],[@b17-cmar-10-2499] suggest that lifestyle changes can correct a low SMI. Consistent with a previous study by Itoh et al,[@b18-cmar-10-2499] we found that SMI correlated with host factors, but not with tumor factors. Additionally, patients with a low SMI may benefit from exercise, and Shin and Lee[@b16-cmar-10-2499] reported that running could reduce IP-10 levels. Other potential interventions include an increased protein intake and the use of (n-3) fatty acids and anti-inflammatory drugs.[@b19-cmar-10-2499] In brief, the potential reversibility and simple evaluability of the SMI merit further attention.

As noted previously, most studies of SMI in patients with colon cancer have been conducted in Western countries,[@b19-cmar-10-2499],[@b20-cmar-10-2499] and we used the cut-off value reported by Feliciano et al[@b5-cmar-10-2499] to classify \~70% of patients in our study as having sarcopenia. Although a recent report proposed a diagnostic algorithm to promote sarcopenia research in Asia,[@b1-cmar-10-2499] the most optimal SMI cut-off value remains controversial. We note that the sex-specific SMI cut-off points used in our study are similar to those used previously in other Asian studies[@b18-cmar-10-2499],[@b20-cmar-10-2499] and recommend additional prospective studies with larger cohorts to identify the optimal value.

Unlike Feliciano et al,[@b5-cmar-10-2499] we did not observe a relationship between the SMI and DFS in patients with stage II colon cancer. We might attribute this discrepancy to the diverse prognoses of patients with stage II colon cancer.[@b21-cmar-10-2499] Additionally, the patients included in the study by Feliciano et al[@b5-cmar-10-2499] were followed for longer than those in our study.

This study had several limitations. First, we applied a retrospective study design and were unable to evaluate the physical performances or muscle strengths of the involved patients. Second, the circulating levels of cytokines were tested only in a cohort of patients with metastatic CRC. Third, as most patients remain alive, we were unable to evaluate overall survival.

Conclusion
==========

In conclusion, this study highlights the correlations of a low SMI with a high systematic inflammation response and IP-10 level. Finally, we identified a low SMI as a predictor of poor DFS in patients with stage III colon cancer.

Data availability
=================

The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform. ([www.researchdata.org.cn](http://www.researchdata.org.cn)), with the approval RDD number as RDDA2018000654.

Supplementary materials
=======================

###### 

The survival data in all 561 patients included in this study.

###### 

Clinical characteristics of patients with available CT scan results and circulating cytokine levels

  Characteristics                 Number of patients
  ------------------------------- --------------------
  Age (years)                     
   ≤50                            40
   51--65                         56
   \>65                           29
  Sex                             
   Male                           83
   Female                         42
  Chemotherapy (the first line)   
   Oxaliplatin-based regimen      85
   Irinotecan-based regimen       40
  Primary tumor response          
   Right-side colon               56
   Left-side colon                69
  Metastatic site                 
   Liver                          93
   Other site                     32
  Histological grade              
   Well/moderate differentiated   76
   Poorly differentiate           49
  CEA (ng/mL)                     
   \<5                            42
   ≥5                             83
  CA19-9 (U/mL)                   
   \<35                           70
   ≥35                            55

**Abbreviations:** CEA, carcinoembryonic antigen; CT, computed tomography.
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![Correlations between the SMI and the leukocyte **(A)**, neutrophil **(B)**, lymphocyte **(C)**, monocyte **(D)**, platelet counts **(E)**, and CRP level **(F)**.\
**Abbreviations:** CRP, C-reactive protein; SMI, skeletal muscle index.](cmar-10-2499Fig1){#f1-cmar-10-2499}

![DFS of patients with stage I + II **(A)** and stage III **(B)** colon cancer, stratified by SMI.\
**Abbreviations:** DFS, disease-free survival; SMI, skeletal muscle index.](cmar-10-2499Fig2){#f2-cmar-10-2499}

![Correlation between the SMI and IP-10 level.\
**Abbreviations:** IP-10, interferon γ-induced protein 10; SMI, skeletal muscle index.](cmar-10-2499Fig3){#f3-cmar-10-2499}

###### 

Correlations between SMI and patients' characteristics

  Variables            Total   SMI          *p*-value[\*](#tfn1-cmar-10-2499){ref-type="table-fn"}   
  -------------------- ------- ------------ -------------------------------------------------------- -------------
  Number of patients   561     280 (49.9)   281 (50.1)                                               
  Age (years)                                                                                        \<**0.001**
   ≤50                 147     61 (41.5)    86 (58.5)                                                
   51--65              246     108 (43.9)   138 (56.1)                                               
   \>65                168     111 (66.1)   57 (33.9)                                                
  Sex                                                                                                1.000
   Male                343     171 (49.9)   172 (50.1)                                               
   Female              218     109 (50.0)   109 (50.0)                                               
  Primary tumor                                                                                      0.108
   Right-side colon    210     95 (45.2)    115 (54.8)                                               
   Left-side colon     346     181 (52.3)   165 (47.7)                                               
   Multiple            5       4 (80.0)     1 (20.0)                                                 
  T stage                                                                                            0.658
   1                   19      8 (42.1)     11 (57.9)                                                
   2                   75      38 (50.7)    37 (49.3)                                                
   3                   382     187 (49.0)   195 (51.0)                                               
   4                   85      47 (55.3)    38 (44.7)                                                
  N stage                                                                                            0.742
   0                   391     191 (48.8)   200 (51.2)                                               
   1                   121     63 (52.1)    58 (47.9)                                                
   2                   49      26 (53.1)    23 (46.9)                                                
  Stage                                                                                              0.634
   I                   76      37 (48.7)    39 (51.3)                                                
   II                  321     156 (48.6)   165 (51.4)                                               
   III                 164     87 (53.0)    77 (47.0)                                                
  Differentiation                                                                                    0.393
   Well/moderate       436     212 (48.6)   224 (51.4)                                               
   Poor                125     68 (54.4)    57 (45.6)                                                
  Mucinous histology                                                                                 0.856
   Yes                 32      17 (53.1)    15 (46.9)                                                
   No                  526     262 (49.8)   264 (50.2)                                               
  Neural invasion                                                                                    0.309
   Absent              467     238 (51.0)   229 (49.0)                                               
   Present             94      42 (44.7)    52 (55.3)                                                
  Venous invasion                                                                                    0.454
   Absent              453     230 (50.8)   223 (49.2)                                               
   Present             108     50 (46.3)    58 (53.7)                                                
  CEA (ng/mL)                                                                                        0.194
   ≤5                  344     164 (47.7)   180 (52.3)                                               
   \>5                 217     116 (53.5)   101 (46.5)                                               
  Tumor size (cm)                                                                                    **0.018**
   ≤2                  41      15 (36.6)    26 (63.4)                                                
   2--5                378     181 (47.9)   197 (52.1)                                               
   \>5                 141     83 (58.9)    58 (41.1)                                                
  MMR status                                                                                         0.797
   dMMR                68      35 (51.5)    33 (48.5)                                                
   pMMR                493     245 (49.7)   248 (50.3)                                               
  BMI                                                                                                \<**0.001**
   \<25                461     255 (55.3)   206 (44.7)                                               
   ≥25                 100     25 (25.0)    75 (75.0)                                                
  Diabetes                                                                                           0.106
   Yes                 126     71 (56.3)    55 (43.7)                                                
   No                  435     209 (48.0)   226 (52.0)                                               
  Hypertension                                                                                       0.435
   Yes                 66      36 (54.5)    30 (45.5)                                                
   No                  495     244 (49.3)   251 (50.7)                                               

**Notes:**

*χ*^2^ test was used to compare patient characteristics, and *p*-value \<0.05 shown in bold was statistically significant.

**Abbreviations:** BMI, body mass index; CEA, carcinoembryonic antigen; MMR, mismatch repair; SMI, skeletal muscle index.

###### 

Correlation between skeletal muscle mass and the local tumor microenvironment

  Tumor microenvironment           Total   SMI          *p*-value[\*](#tfn3-cmar-10-2499){ref-type="table-fn"}   
  -------------------------------- ------- ------------ -------------------------------------------------------- -----------
  Carcinoma percentage                                                                                           0.129
   Low                             152     84 (55.3)    68 (44.7)                                                
   High                            409     196 (47.9)   213 (52.1)                                               
  Neutrophil -- central region                                                                                   0.665
   Low grade                       216     105 (48.6)   111 (51.4)                                               
   High grade                      345     175 (50.7)   170 (49.3)                                               
  Neutrophil -- invasive margin                                                                                  0.339
   Low grade                       348     168 (48.3)   180 (51.7)                                               
   High grade                      213     112 (52.6)   101 (47.4)                                               
  Lymphocytes -- central region                                                                                  0.263
   Low grade                       223     118 (52.9)   105 (47.1)                                               
   High grade                      338     162 (47.9)   176 (52.1)                                               
  Lymphocytes -- invasive margin                                                                                 0.735
   Low grade                       265     130 (49.1)   135 (51.0)                                               
   High grade                      296     150 (50.7)   146 (49.3)                                               
  Crohn's-like reaction                                                                                          0.773
   Yes                             53      25 (47.2)    28 (52.8)                                                
   No                              505     254 (50.3)   251 (49.7)                                               
  NLR                                                                                                            **0.021**
   ≤3                              394     184 (46.7)   210 (53.3)                                               
   \>3                             167     96 (57.5)    71 (42.5)                                                
  CRP                                                                                                            0.129
   Normal                          410     199 (48.5)   211 (51.5)                                               
   Elevated                        151     81 (53.6)    70 (46.4)                                                
  Albumin                                                                                                        **0.006**
   Normal                          496     237 (47.8)   259 (52.2)                                               
   Decreased                       65      43 (66.2)    22 (33.8)                                                

**Notes:**

χ^2^ test was used to compare patient characteristics, and *p*-value \<0.05 shown in bold was statistically significant.

**Abbreviations:** CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; SMI, skeletal muscle index.

###### 

Multivariate analysis of prognostic factors in patients with stage III colon cancer

  Variables   *B*      *p*-value      Exp (*B*)   95% CI for exp (*B*)
  ----------- -------- -------------- ----------- ----------------------
  Age         0.289    0.199          1.334       0.859--2.073
  Sex         0.177    0.608          1.193       0.608--2.341
  T stage     0.097    0.746          1.102       0.612--1.987
  N stage              0.531                      
   N1         1.187    0.285          3.278       0.371--28.918
   N2         −0.035   0.928          0.966       0.457--2.040
  NLR         −0.266   0.553          0.766       0.318--1.847
  CEA         0.260    0.455          1.297       0.656--2.564
  SMI         0.734    [0.039]{.ul}   2.083       1.037--4.186

**Abbreviations:** CEA, carcinoembryonic antigen; Exp (*B*), exponent of *B*; NLR, neutrophil-to-lymphocyte ratio; SMI, skeletal muscle index.
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